Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) Director Sells 3,377 Shares of Stock

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) Director Jeffrey W. Dunn sold 3,377 shares of the company's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $19.05, for a total value of $64,331.85. Following the sale, the director now owns 17,354 shares in the company, valued at approximately $330,593.70. This trade represents a 16.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

SI-BONE Stock Down 0.8%

Shares of NASDAQ SIBN traded down $0.16 during mid-day trading on Friday, reaching $18.90. The company had a trading volume of 485,058 shares, compared to its average volume of 382,655. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The stock has a market capitalization of $805.42 million, a PE ratio of -20.54 and a beta of 0.82. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $20.05. The stock's 50 day moving average is $16.00 and its 200-day moving average is $15.47.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. The business had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. As a group, equities analysts anticipate that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on SIBN shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of SI-BONE in a report on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 target price on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Truist Financial boosted their price objective on SI-BONE from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. increased its position in SI-BONE by 11.1% during the first quarter. American Century Companies Inc. now owns 2,642,322 shares of the company's stock worth $37,072,000 after buying an additional 264,254 shares during the last quarter. Vanguard Group Inc. raised its position in shares of SI-BONE by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 2,444,159 shares of the company's stock worth $34,292,000 after acquiring an additional 35,349 shares in the last quarter. Silvercrest Asset Management Group LLC increased its position in SI-BONE by 21.9% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock valued at $27,392,000 after buying an additional 350,970 shares in the last quarter. First Light Asset Management LLC boosted its stake in SI-BONE by 41.8% during the 1st quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company's stock valued at $22,622,000 after purchasing an additional 475,426 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY raised its holdings in shares of SI-BONE by 5.3% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company's stock worth $19,432,000 after purchasing an additional 69,831 shares during the period. 98.11% of the stock is currently owned by institutional investors.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.